







VALIDATE-BSI 2019 Conference: Vaccine Development for Neglected Intracellular Pathogens













VENUE: The Grand Hall & Winter Gardens at The Drum at Wembley, London
<https://www.thedrumatwembley.com/>

Wednesday 2 October 2019 (afternoon and evening)









1200		<i>Registration and buffet lunch for all delegates</i>
1300		Prof Helen McShane VALIDATE Director, University of Oxford, UK Welcome to conference & introduction to VALIDATE
1310		Dr Doug Brown Chief Executive, British Society for Immunology, UK BSI Welcome address
1320		Session 1: Tissue-specific immunity, host-pathogen interactions, macrophages and the microenvironment (Chair: Prof Andrea Cooper , University of Leicester, UK)
1320		Keynote speaker: Prof Clare Lloyd Imperial College London, UK Local and environmental cues dictate the nature of the pulmonary immune response
1400		Dr Barbara Kronsteiner-Dobramysl University of Oxford, UK Diabetes alters cellular metabolism of T cells: implications for vaccine development








1420		Dr Chidchamai Kewcharoenwong Khon Kaen University, Thailand Glibenclamide alters cytokine production of primary human monocytes from diabetic individuals against Mycobacterium tuberculosis infection
1440		Dr Isadora Lima FIOCRUZ, Brazil Canine visceral leishmaniasis: the role of tissue-specific immunity in the progression of disease
1500		<i>Tea/coffee break</i>
1530		Keynote speaker: Prof Tracy Hussell University of Manchester, UK Innate sensing of lung health and disease
1610		Dr Lisa Stockdale University of Oxford, UK Cytomegalovirus as a correlate of risk for TB?
1630		Poster turbo talks:
1630		Asst Prof Kiran Afshan Quaid-i-Azam University, Pakistan To be confirmed
1634		Dr Anthony Afum-Adjei Awuah Kumasi Centre for Collaborative Research (KCCR), Ghana Why fix when you can prevent; towards TB Vaccines Research in Ghana
1638		Dr Federico Carlos Blanco National Institute of Agricultural Technology (INTA), Argentina The isolate Mb04-303 induce a proinflammatory innate immune profile and is a potential candidate for an attenuated mutant vaccine against bovine tuberculosis
1642		Assoc Prof Mary Burtnick University of Nevada, Reno, USA Optimization of melioidosis subunit vaccines using <i>Burkholderia thailandensis</i> E555
1646		Dr Panjaporn Chaichana MORU, Thailand Identification of protective antibody profiles for vaccine development against melioidosis
1650		Assoc Prof Narisara Chantratita Mahidol University, Thailand Risk of <i>Burkholderia pseudomallei</i> infection, host immune response and biomarkers for melioidosis

1654		Asst Prof Ganjana Lertmemongkolcha Khon Kaen University, Thailand Metformin-induced suppression of IFN- α expression via mTORC1 signalling following seasonal vaccination is associated with impaired antibody responses in diabetes mellitus
1658		Dr Rachel Okojie University of Benin, Nigeria Comparative study of the immunological and haematological parameters among tuberculosis naive and treated patients in Central Hospital, Benin City, Nigeria
1702		Dr Olayinka Osuolale Elizade University, Nigeria Leishmaniasis in patients attending a medical health center in the rural community of Ilara-Mokin, Ondo State, Nigeria
1706		Asst Prof Vijay Kumar Prajapati Central University of Rajasthan, India Evaluation of immunogenicity of the engineered multi-epitope subunit vaccine against visceral leishmaniasis infection
1710		Dr Lok Bahadur Shrestha BP Koirala Institute of Health Sciences, Nepal Emerging Clinical Microbiologist looking for research opportunity in TB Vaccinology
1714		Dr Suwarti Eijkman Oxford Clinical Research Unit (EOCRU), Indonesia Intranasal boosting regimen of Human Parainfluenza Virus Type 2-Ag85B vaccines induces superior CD4 immune response against <i>Mycobacterium tuberculosis</i>
1718		Dr Julen Tomás Cortázar University College Dublin, Ireland Elucidating the mechanisms of protection of the <i>Burkholderia pseudomallei</i> antigen, BpOmpW
1722		Chathika Weersuriya LSHTM, UK Mathematical modelling of the epidemiological impact, cost-effectiveness and budget impact of novel tuberculosis vaccines on multi-drug resistant tuberculosis
1730		Group photograph
		Drinks reception with poster session (see website for list of poster presenters and abstracts)
1900+		Conference Dinner

Thursday 3 October 2019 (full day)

Start	End	Meeting
0830		Coffee/tea
0900		Session 2: Biomarkers (including omics & Big Data) (Chair: Prof Helen Fletcher, LSHTM, UK)
0900		Keynote speaker: Dr January Weiner Berlin Institute of Health, Germany Biomarkers in tuberculosis and individual variability of the host
0940		Dr Fatoumatta Darboe MRC The Gambia Predicting and diagnosing TB disease in HIV-infected persons
1000		Dr Eduardo Milton Ramos Sanchez USP, Brazil Altered expression of microRNAs in infections with cutaneous and visceral strains of Leishmania
1020		Tea/coffee break
1050		Keynote speaker: Prof Stephen Gordon University College Dublin, Ireland One Health route to exploring virulence in the <i>Mycobacterium tuberculosis</i> complex
1130		Hannah Painter LSHTM, UK Development of an ex vivo mycobacterial inhibition assay using murine lung cells for tuberculosis vaccine testing
1150		Asst Prof Tufária Mussa Eduardo Mondlane University, Mozambique The fusion protein Ag85B-HBHA (FP1) elicits IFN- γ , IL-2 and TNF- α in conventional T cells of tuberculosis contacts with latent infection over time
1210	1310	Lunch
1310		Session 3: Latest vaccine developments (Chair: Prof Helen McShane , University of Oxford, UK)
1310		Keynote speaker: Assoc Prof Paul Brett University of Nevada, Reno, USA Development of multivalent subunit vaccines for immunization against melioidosis
1350		Dr Sophie Rhodes LSHTM, UK Dose finding for new vaccines: the role for immunostimulation/immunodynamic modelling

1410		Dr Deepa Paliwal University of Reading, UK Progress in reverse vaccinology approach for bovine TB
1430	1500	<i>Tea/coffee break</i>
1500		Keynote speaker: Prof Mark Hatherill University of Cape Town, South Africa Major advances and next steps for tuberculosis vaccine development
1540		Dr Justice Boakye-Appiah SGUL, UK Mycolactone based vaccine against Buruli ulcer disease
1600		Asst Prof Rebecca Harris LSHTM, UK Potential impact of new tuberculosis vaccines in China, South Africa and India and implications for vaccine development
1620		Prof Helen McShane VALIDATE Director, University of Oxford, UK Wrap up and conference close
1630		End of conference

Conference Registration charges:

- 1) VALIDATE and/or BSI members:
 - a) Non-industry members:
 - i) LMIC members Free
 - ii) Non-LMIC members £50
 - b) Industry members £75
- 2) Non-members of VALIDATE or BSI £100

To register, visit: <https://www.validate-network.org/annual-meeting>

